Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

Silvio Danese (Corresponding Author), Remo Panaccione, Brian G. Feagan, GALAXI-1 Study Group, Juris Pokrotnieks (Member of the Working Group)

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science